AU2003240746A1 - Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases

Info

Publication number
AU2003240746A1
AU2003240746A1 AU2003240746A AU2003240746A AU2003240746A1 AU 2003240746 A1 AU2003240746 A1 AU 2003240746A1 AU 2003240746 A AU2003240746 A AU 2003240746A AU 2003240746 A AU2003240746 A AU 2003240746A AU 2003240746 A1 AU2003240746 A1 AU 2003240746A1
Authority
AU
Australia
Prior art keywords
diagnostic
neurodegenerative diseases
therapeutic use
regulatory protein
acute regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003240746A
Other versions
AU2003240746A8 (en
Inventor
Thomas Hesterkamp
Ralf Krappa
Johannes Pohlner
Heinz Von Der Kammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of AU2003240746A1 publication Critical patent/AU2003240746A1/en
Publication of AU2003240746A8 publication Critical patent/AU2003240746A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003240746A 2002-06-10 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases Abandoned AU2003240746A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38672102P 2002-06-10 2002-06-10
EP02012815.3 2002-06-10
US60/386,721 2002-06-10
EP02012815 2002-06-10
PCT/EP2003/005910 WO2003104811A2 (en) 2002-06-10 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2003240746A1 true AU2003240746A1 (en) 2003-12-22
AU2003240746A8 AU2003240746A8 (en) 2003-12-22

Family

ID=56290436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003240746A Abandoned AU2003240746A1 (en) 2002-06-10 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases

Country Status (4)

Country Link
EP (1) EP1512013A2 (en)
JP (1) JP2005531305A (en)
AU (1) AU2003240746A1 (en)
WO (1) WO2003104811A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005187A1 (en) * 2022-07-01 2024-01-04 田辺三菱製薬株式会社 Composition and method for evaluating responsiveness of edaravone
KR20240035189A (en) * 2022-09-08 2024-03-15 차의과학대학교 산학협력단 Biomarkers for the diagnosis of infertility in elderly women and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
PT1073432E (en) * 1998-04-14 2007-10-22 Gen Hospital Corp Use of d-serine or d-alanine for treating schizophrenia
IL129734A0 (en) * 1999-05-03 2000-02-29 Compugen Ltd Novel nucleic acid and amino acid sequences
AU1159601A (en) * 1999-11-03 2001-05-14 Metris Therapeutics Limited Agents implicated in endometriosis

Also Published As

Publication number Publication date
AU2003240746A8 (en) 2003-12-22
WO2003104811A3 (en) 2004-10-14
EP1512013A2 (en) 2005-03-09
JP2005531305A (en) 2005-10-20
WO2003104811A2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
EP1578421A4 (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
AU2003268531A1 (en) Materials and methods for treatment of allergic diseases
AU2003267532A1 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF Alpha-SYNUCLEIN-RELATED DISEASES
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
AU2003246380A1 (en) Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
AU2003260301A1 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003279312A1 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003278497A1 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU2003257398A1 (en) Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
AU2003240746A1 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
AU2003224080A1 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
AU2003242588A1 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE
AU2003222849A1 (en) Diagnostic and therapeutic use of ensadin-0255 gene and protein for neurodegenerative diseases
AU2003222842A1 (en) Diagnostic and therapeutic use of ensadin-0138 gene and protein for neurodegenerative diseases
AU2003260460A1 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
AU2002364757A1 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU2003232200A1 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
AU2003224095A1 (en) Diagnostic and therapeutic use of an atp-binding cassette gene and protein for neurodegenerative diseases
AU2003247252A1 (en) Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases
AU2003271568A1 (en) Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase